

**AMENDMENTS TO THE CLAIMS**

1. (currently amended) A cytotherapeutic unit suitable for treatment of a patient in need of hematopoietic cells comprising at least one CD34+ cell or at least one CD8+ cell within a plurality of potent cells; the ~~content~~contents of said unit being known with respect to the identities and numbers of at least some of said plurality; the unit being assayed to ensure the accuracy of said identities and numbers; and the unit comprising cells from a plurality of sources, wherein one source of said plurality of sources is fetal cord blood, fetal tissue, a placenta, a postpartum placenta, or postpartum placenta perfusate.
2. (original) The cytotherapeutic unit of claim 1 wherein the accuracy of the assay is certified by the provider of the unit.
3. (original) The cytotherapeutic unit of claim 1 wherein the potent cells for which the identities and numbers are known are pluripotent cells.
4. (original) The cytotherapeutic unit of claim 1 wherein said identities reflect the presence or absence of at least one antigenic determinant on identified cells.
5. (previously presented) The cytotherapeutic unit of claim 1 wherein said unit comprises potent cells obtained from fetal cord blood or fetal tissue.
6. (previously presented) The cytotherapeutic unit of claim 1 wherein said unit comprises potent cells obtained from fetal cord blood.
7. (previously presented) The cytotherapeutic unit of claim 1 wherein at least some of said potent cells are obtained from a placenta.
8. (previously presented) The cytotherapeutic unit of claim 1 wherein at least some of said potent cells are obtained from a postpartum placenta.
9. (previously presented) The cytotherapeutic unit of claim 1 wherein at least some of said potent cells are obtained from postpartum placenta perfusate.

10-11. (cancelled)

12. (currently amended) The cytotherapeutic unit of claim 1 wherein said potent cells are obtained from at least two individuals.

13. (currently amended) The cytotherapeutic unit of claim 1 wherein said potent cells are obtained from at least ~~five~~ individuals.

14. (cancelled)

15. (original) The cytotherapeutic unit of claim 1 wherein at least one type of cell is excluded from the unit.

16. (original) The cytotherapeutic unit of claim 1 wherein the plurality of potent cells is selected to render the cytotherapeutic unit suitable for therapy for an indicated disease state or condition.

17. (original) The cytotherapeutic unit of claim 16 wherein at least one type of cell is excluded from the unit.

18. (currently amended) A cytotherapeutic unit suitable for treatment of a patient in need of hematopoietic cells comprising at least two preselected types of potent cells, said unit comprising cells from a plurality of sources, wherein one source of said plurality of sources is fetal cord blood, fetal tissue, a placenta, a postpartum placenta, or postpartum placenta perfusate and wherein at least one cell is CD34+ or at least one cell is CD8+.

19. (cancelled)

20. (currently amended) The cytotherapeutic unit of claim 18, distributed with a certification of the contents of said cytotherapeutic unit~~wherein the contents of preselected potent cells are certified.~~

21. (currently amended) The cytotherapeutic unit of claim ~~18~~20 wherein ~~at least one type of cell is excluded from the unit~~said certification comprises an indication of cells excluded from said cytotherapeutic unit.

22. (currently amended) The cytotherapeutic unit of claim ~~21~~20 wherein ~~the contents of preselected potent cells and the absence the types of cells to be excluded are the subject of a certification~~said certification comprises an indication of cells absent from said cytotherapeutic unit.

23. (currently amended) The cytotherapeutic unit of claim ~~22~~20, wherein said certification ~~is of a plurality of potent cell types, said plurality and the numbers of each of said plurality being selected~~indicates how the presence, absence, and/or exclusion of certain cell types to render or renders the cytotherapeutic unit suitable for therapy for an indicated disease state or condition.

24-30. (cancelled)

31. (currently amended) A cytotherapeutic unit suitable for treatment of a patient in need of hematopoietic cells comprising (a) cells obtained from umbilical cord blood and (b) cells obtained from a placenta, wherein at least one type of cell has been removed from the unit, and wherein at least one cell remaining in the unit is CD34+ or at least one cell remaining in the unit is CD8+.

32. (currently amended) The cytotherapeutic unit of claim 31 wherein a plurality of cell types have~~has~~ been removed from the unit.

33. (cancelled)

34. (currently amended) A cytotherapeutic unit suitable for treatment of a patient in need of hematopoietic cells comprising (a) cells obtained from umbilical cord blood or (b) cells obtained from a placenta or (c) a mixture of cells ~~derived from~~obtained from umbilical cord blood and cells obtained from a placenta, said cells comprising a plurality of different types, at least ~~someone~~ of the different types having been obtained from a source that differs from a source of another type and wherein at least

one cell is CD34+ or at least one cell is CD8+ having been separated into components and recombined into said unit.

35. (currently amended) The cytotherapeutic unit of claim 34, wherein at least one of said types of cells~~said separated cell types have~~ has been frozen separately from another type of cells.

36. (original) The cytotherapeutic unit of claim 34, in a frozen state.

37. (currently amended) The cytotherapeutic unit of claim 34, wherein at least one of said separated cell types cells ~~have~~has been characterized.

38-49. (cancelled)

50. (currently amended) A library of cytotherapeutic units suitable for treatment of a patient in need of hematopoietic cells, each unit member of said library comprising a plurality of potent cells; each of said units comprising cells from a plurality of sources, wherein one source of said plurality of sources is fetal cord blood, fetal tissue, a placenta, a postpartum placenta, or postpartum placenta perfusate; the content of each of said units being known with respect to the identities and numbers at least some of the plurality of potent cells comprising said unit; each of said units being assayed to ensure the accuracy of said identities and numbers; and each of said units comprising at least one CD34+ cell or at least one CD8+ cell.

51-53. (cancelled)